Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lin

Showing results (251-260 of 287) with videos related to

Pageof 29
Sort By:
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Archives of Pathology & Laboratory Medicine|August 6, 2014
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer FoundationMahul B Amin, Daniel W Lin, John L Gore, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.
Neoplasia (New York, N.Y.)|May 30, 2026
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancerLisha G Brown, Ilsa M Coleman, Tony L H Chu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2024
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective CohortMichael A Liss, Nicole Zeltser, Yingye Zheng, et al.
Human Pathology|February 17, 2022
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosisSamuel Ruder, Yan Gao, Yi Ding, et al.
Pageof 29

Showing results (251-260 of 287) with videos related to

Sort By:
Pageof 29
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Archives of Pathology & Laboratory Medicine|August 6, 2014
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer FoundationMahul B Amin, Daniel W Lin, John L Gore, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.
Neoplasia (New York, N.Y.)|May 30, 2026
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancerLisha G Brown, Ilsa M Coleman, Tony L H Chu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2024
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective CohortMichael A Liss, Nicole Zeltser, Yingye Zheng, et al.
Human Pathology|February 17, 2022
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosisSamuel Ruder, Yan Gao, Yi Ding, et al.
Pageof 29